Antibiofilm activity of four hemibastadin analogues was evaluated against a clinical Candida albicans strain. Three of four analogues demonstrated significant antibiofilm effects, with EC50 values of 34.4 ± 9.6 μM for the most efficient. This most active compounds notably reduced both the biovolume and thickness of the biofilm. Importantly, antifungal susceptibility testing confirmed that the observed effects were specific to biofilm inhibition and not due to general antifungal activity. These results, comparable to those obtained with biofilms of marine Gram-negative bacteria, highlight the potential of hemibastadin analogues as promising lead compounds for the development of broad-spectrum antibiofilm including Candida albicans without exerting selective pressure for antimicrobial resistance.
References
[1]
Bjarnsholt, T. (2013) The Role of Bacterial Biofilms in Chronic Infections. APMIS, 121, 1-58. https://doi.org/10.1111/apm.12099
[2]
Bjarnsholt, T., Buhlin, K., Dufrêne, Y.F., Gomelsky, M., Moroni, A., Ramstedt, M., et al. (2018) Biofilm Formation—What We Can Learn from Recent Developments. JournalofInternalMedicine, 284, 332-345. https://doi.org/10.1111/joim.12782
[3]
Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T. and Ghannoum, M.A. (2001) Biofilm Formation by the Fungal Pathogen candidaAlbicans: Development, Architecture, and Drug Resistance. JournalofBacteriology, 183, 5385-5394. https://doi.org/10.1128/jb.183.18.5385-5394.2001
[4]
Calderone, R.A. and Fonzi, W.A. (2001) Virulence Factors of Candida Albicans. TrendsinMicrobiology, 9, 327-335. https://doi.org/10.1016/s0966-842x(01)02094-7
[5]
Kim, J. and Sudbery, P. (2011) Candida Albicans, a Major Human Fungal Pathogen. TheJournalofMicrobiology, 49, 171-177. https://doi.org/10.1007/s12275-011-1064-7
[6]
Dominguez, E.G. and Andes, D.R. (2017) Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms. In: Prasad, R., Ed., Candidaalbicans: CellularandMolecularBiology, Springer International Publishing, 77-92. https://doi.org/10.1007/978-3-319-50409-4_6
[7]
Nobile, C.J. and Johnson, A.D. (2015) Candidaalbicans Biofilms and Human Disease. AnnualReviewofMicrobiology, 69, 71-92. https://doi.org/10.1146/annurev-micro-091014-104330
[8]
Yebra, D.M., Kiil, S. and Dam-Johansen, K. (2004) Antifouling Technology—Past, Present and Future Steps Towards Efficient and Environmentally Friendly Antifouling Coatings. ProgressinOrganicCoatings, 50, 75-104. https://doi.org/10.1016/j.porgcoat.2003.06.001
[9]
Li, X. and Lee, J. (2017) Antibiofilm Agents: A New Perspective for Antimicrobial Strategy. JournalofMicrobiology, 55, 753-766. https://doi.org/10.1007/s12275-017-7274-x
Copp, B.R., Ireland, C.M. and Barrows, L.R. (1992) Psammaplysin, C: A New Cytotoxic Di-Bromotyrosine-Derived Metabolite from the Marine Sponge Druinella (=Psammaplysilla) Purpurea. Journal of Natural Products, 55, 822-823.
[12]
Peng, J., Li, J. and Hamann, M.T. (2005) The Marine Bromotyrosine Derivatives. The Alkaloids: Chemistry and Biology, 61, 59-262.
[13]
Andjouh, S. and Blache, Y. (2015) Click-Based Synthesis of Bromotyrosine Alkaloid Analogs as Potential Anti-Biofilm Leads for SAR Studies. Bioorganic&MedicinalChemistryLetters, 25, 5762-5766. https://doi.org/10.1016/j.bmcl.2015.10.073
[14]
Agalave, S.G., Maujan, S.R. and Pore, V.S. (2011) Click Chemistry: 1,2,3‐Triazoles as Pharmacophores. Chemistry—AnAsianJournal, 6, 2696-2718. https://doi.org/10.1002/asia.201100432
[15]
Bonandi, E., Christodoulou, M.S., Fumagalli, G., Perdicchia, D., Rastelli, G. and Passarella, D. (2017) The 1,2,3-Triazole Ring as a Bioisostere in Medicinal Chemistry. DrugDiscoveryToday, 22, 1572-1581. https://doi.org/10.1016/j.drudis.2017.05.014
[16]
Kacou, A., Ouvrard, A., Jamet, D., Jamet, J.‐. and Blache, Y. (2019) Towards Eco‐friendly Biocides: Preparation, Antibiofilm Activity of Hemibastadin Analogues. LettersinAppliedMicrobiology, 68, 360-368. https://doi.org/10.1111/lam.13150
[17]
Pierce, C.G., Uppuluri, P., Tristan, A.R., Wormley, F.L., Mowat, E., Ramage, G., et al. (2008) A Simple and Reproducible 96-Well Plate-Based Method for the Formation of Fungal Biofilms and Its Application to Antifungal Susceptibility Testing. NatureProtocols, 3, 1494-1500. https://doi.org/10.1038/nprot.2008.141
[18]
Ramage, G., Vande Walle, K., Wickes, B.L. and López-Ribot, J.L. (2001) Standardized Method for inVitro Antifungal Susceptibility Testing of candidaAlbicans Biofilms. AntimicrobialAgentsandChemotherapy, 45, 2475-2479. https://doi.org/10.1128/aac.45.9.2475-2479.2001
[19]
Tan, Y., Leonhard, M., Ma, S. and Schneider-Stickler, B. (2016) Influence of Culture Conditions for Clinically Isolated Non-Albicans Candida Biofilm Formation. JournalofMicrobiologicalMethods, 130, 123-128. https://doi.org/10.1016/j.mimet.2016.09.011
[20]
Heydorn, A., Nielsen, A.T., Hentzer, M., Sternberg, C., Givskov, M., Ersbøll, B.K., et al. (2000) Quantification of Biofilm Structures by the Novel Computer Program Comstat. Microbiology, 146, 2395-2407. https://doi.org/10.1099/00221287-146-10-2395
[21]
Vorregaard, M. (2008) Comstat2—A Modern 3D Image Analysis Environment for Biofilms. Technical University of Denmark: Kongens Lyngby, Denmark.
[22]
Pfaller, M.A. (2002) National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard. National Committee for Clinical Laboratory Standards.
[23]
Zanni, P.C.M.D., Bonfim-Mendonça, P.d.S., Negri, M., Nakamura, S.S., Donatti, L., Svidzinski, T.I.E., et al. (2017) Virulence Factors and Genetic Variability of Vaginal Candida Albicans Isolates from HIV-Infected Women in the Post-Highly Active Antiretroviral Era. RevistadoInstitutodeMedicinaTropicaldeSãoPaulo, 59, 1-10. https://doi.org/10.1590/s1678-9946201759044
[24]
Kacou, A., Yapi, A. and Blache, Y. (2026) Hemibastadin Alkaloid Analogues as Potential Anti-Biofilm Leads against Multi-Species Biofilms. OpenJournalofMedicinalChemistry, 16, 1-14. https://doi.org/10.4236/ojmc.2026.161001
